The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges
Recurrent pericarditis is a common complication of acute pericarditis (15–30%) for which, in most cases, no underlying etiology is found [idiopathic recurrent pericarditis (IRP)]. IRP is currently viewed as an autoinflammatory disease with characteristic recurrent episodes of sterile inflammation. A...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00078/full |
| _version_ | 1819259647723307008 |
|---|---|
| author | George Lazaros Katerina Antonatou Dimitrios Vassilopoulos |
| author_facet | George Lazaros Katerina Antonatou Dimitrios Vassilopoulos |
| author_sort | George Lazaros |
| collection | DOAJ |
| description | Recurrent pericarditis is a common complication of acute pericarditis (15–30%) for which, in most cases, no underlying etiology is found [idiopathic recurrent pericarditis (IRP)]. IRP is currently viewed as an autoinflammatory disease with characteristic recurrent episodes of sterile inflammation. According to the most recent Guidelines, the initial treatment regimen consists of a combination of aspirin or non-steroidal anti-inflammatory drugs with colchicine followed by the addition of corticosteroids in resistant or intolerant cases. Despite this treatment approach, a number of patients either do not respond or cannot tolerate the above therapies. For this refractory group, small case series and a recent randomized controlled trial have shown that interleukin-1 inhibition with anakinra is a rapidly acting, highly efficient, steroid-sparing, and safe therapeutic intervention. In this perspective, we discuss the available clinical evidence and our own clinical experience as well as the future prospects of this novel therapeutic approach for patients with IRP. |
| first_indexed | 2024-12-23T19:13:20Z |
| format | Article |
| id | doaj.art-6f55cea56e394922895e08b29083aaa4 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-23T19:13:20Z |
| publishDate | 2017-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-6f55cea56e394922895e08b29083aaa42022-12-21T17:34:23ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2017-06-01410.3389/fmed.2017.00078273394The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future ChallengesGeorge Lazaros0Katerina Antonatou1Dimitrios Vassilopoulos21st Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, GreeceJoint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, GreeceJoint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, GreeceRecurrent pericarditis is a common complication of acute pericarditis (15–30%) for which, in most cases, no underlying etiology is found [idiopathic recurrent pericarditis (IRP)]. IRP is currently viewed as an autoinflammatory disease with characteristic recurrent episodes of sterile inflammation. According to the most recent Guidelines, the initial treatment regimen consists of a combination of aspirin or non-steroidal anti-inflammatory drugs with colchicine followed by the addition of corticosteroids in resistant or intolerant cases. Despite this treatment approach, a number of patients either do not respond or cannot tolerate the above therapies. For this refractory group, small case series and a recent randomized controlled trial have shown that interleukin-1 inhibition with anakinra is a rapidly acting, highly efficient, steroid-sparing, and safe therapeutic intervention. In this perspective, we discuss the available clinical evidence and our own clinical experience as well as the future prospects of this novel therapeutic approach for patients with IRP.http://journal.frontiersin.org/article/10.3389/fmed.2017.00078/fullpericarditistherapeuticsinterleukin-1betahereditary autoinflammatory diseasesinterleukin-1 receptor antagonist protein |
| spellingShingle | George Lazaros Katerina Antonatou Dimitrios Vassilopoulos The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges Frontiers in Medicine pericarditis therapeutics interleukin-1beta hereditary autoinflammatory diseases interleukin-1 receptor antagonist protein |
| title | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges |
| title_full | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges |
| title_fullStr | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges |
| title_full_unstemmed | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges |
| title_short | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges |
| title_sort | therapeutic role of interleukin 1 inhibition in idiopathic recurrent pericarditis current evidence and future challenges |
| topic | pericarditis therapeutics interleukin-1beta hereditary autoinflammatory diseases interleukin-1 receptor antagonist protein |
| url | http://journal.frontiersin.org/article/10.3389/fmed.2017.00078/full |
| work_keys_str_mv | AT georgelazaros thetherapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges AT katerinaantonatou thetherapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges AT dimitriosvassilopoulos thetherapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges AT georgelazaros therapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges AT katerinaantonatou therapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges AT dimitriosvassilopoulos therapeuticroleofinterleukin1inhibitioninidiopathicrecurrentpericarditiscurrentevidenceandfuturechallenges |